创新靶向生物制剂落地为中国重度哮喘患者带来福音
中新网上海1月12日电(记者 陈静) 创新靶向生物制剂——新可来#174;(美泊利珠单抗注射液)在华获批用于成人和12岁及以上青少年重度嗜酸粒细胞性哮喘(SEA)维持治疗。记者12日获悉，美泊利珠单抗注射液在上海开出首张处方，为中国重度嗜酸粒细胞性哮喘患者带来了新的希望。
据悉，美泊利珠单抗注射液是一种靶向生物制剂，能够有效抑制嗜酸粒细胞的活性，从而减轻哮喘症状。该药物在全球范围内已经获得批准用于治疗多种类型的哮喘，包括重度嗜酸粒细胞性哮喘。此次在中国获得批准，意味着中国的重度哮喘患者将有更多的治疗选择。
据医学专家介绍，嗜酸粒细胞性哮喘是一种常见的哮喘类型，患者常常会出现气喘、咳嗽、胸闷等症状。传统的药物治疗虽然能够缓解症状，但是并不能从根本上解决问题。而靶向生物制剂则能够针对病因进行治疗，从根本上改善患者的生活质量。
英语如下：
Title: Innovative Targeted Biologic “Xin Ke Lai” Approved in China, Bringing New Hope to Severe Asthmatic Patients
Keywords: Innovative targeted biologic, Mepolizumab injection, Severe eosinophilic asthma
Content: Innovative targeted biologic brings good news to Chinese severe asthma patients
SHANGHAI, Jan. 12 (Reporter Chen Jing) – The innovative targeted biologic, Xin Ke Lai (Mepolizumab injection), has been approved for maintenance treatment of severe eosinophilic asthma (SEA) in adults and adolescents aged 12 and above in China. Reporters learned on the 12th that Mepolizumab injection was prescribed for the first time in Shanghai, bringing new hope to Chinese patients with severe eosinophilic asthma.
It is reported that Mepolizumab injection is a targeted biologic agent that can effectively inhibit the activity of eosinophils, thereby reducing asthma symptoms. The drug has been approved worldwide for the treatment of various types of asthma, including severe eosinophilic asthma. This approval in China means that Chinese patients with severe asthma will have more treatment options.
According to medical experts, eosinophilic asthma is a common type of asthma, and patients often experience symptoms such as wheezing, coughing, and chest tightness. Although traditional drug therapy can alleviate symptoms, it does not fundamentally solve the problem. Targeted biologic agents can target the cause of the disease for treatment, fundamentally improving the quality of life of patients.
【来源】http://www.chinanews.com/life/2024/01-12/10145317.shtml
Views: 1